Entrada Therapeutics Announced Preliminary Data From Its Phase 1 Trial For ENTR-601-44-101 In Healthy Volunteers, On Track To Submit Regulatory Applications In Q4 2024 To Initiate Separate Two Phase 2 Trials In Duchenne Muscular Dystrophy Patients
Portfolio Pulse from Benzinga Newsdesk
Entrada Therapeutics announced positive preliminary data from its Phase 1 trial for ENTR-601-44-101 in healthy volunteers. The drug was well-tolerated with no serious adverse events and showed promising plasma and muscle concentrations. The company plans to submit regulatory applications in Q4 2024 to initiate Phase 2 trials in Duchenne Muscular Dystrophy patients.
June 24, 2024 | 10:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Entrada Therapeutics reported positive preliminary data from its Phase 1 trial for ENTR-601-44-101, showing no serious adverse events and promising drug concentrations. The company plans to submit regulatory applications in Q4 2024 to initiate Phase 2 trials.
The positive Phase 1 trial results and the absence of serious adverse events are likely to boost investor confidence in Entrada Therapeutics. The planned regulatory filings for Phase 2 trials in Q4 2024 further indicate progress and potential future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100